Compare Stocks: HOWL, ACRV, IBIO, and CYPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.95 +5.4%	$1.68	$1.27 ▼ $3.56	$83.46M	1.85	305,636 shs	753,296 shs
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.40M	0.09	1.27 million shs	561,961 shs
HOWL Werewolf Therapeutics	$0.40 +4.8%	$0.38	$0.27 ▼ $2.38	$19.67M	0.29	622,779 shs	274,517 shs
IBIO iBio	$1.43 +2.1%	$1.53	$0.67 ▼ $3.82	$71.04M	1.31	572,355 shs	521,758 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	+12.72%	+11.43%	+10.17%	+48.85%
CYPH Cypherpunk Technologies	0.00%	-6.48%	-9.61%	-40.65%	+89.97%
HOWL Werewolf Therapeutics	0.00%	+1.91%	+10.00%	-21.43%	-70.02%
IBIO iBio	0.00%	+1.42%	+5.93%	-2.72%	+142,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.95 +5.4%	$1.68	$1.27 ▼ $3.56	$83.46M	1.85	305,636 shs	753,296 shs
CYPH Cypherpunk Technologies	$0.64 -0.6%	$0.68	$0.25 ▼ $3.70	$69.40M	0.09	1.27 million shs	561,961 shs
HOWL Werewolf Therapeutics	$0.40 +4.8%	$0.38	$0.27 ▼ $2.38	$19.67M	0.29	622,779 shs	274,517 shs
IBIO iBio	$1.43 +2.1%	$1.53	$0.67 ▼ $3.82	$71.04M	1.31	572,355 shs	521,758 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	+12.72%	+11.43%	+10.17%	+48.85%
CYPH Cypherpunk Technologies	0.00%	-6.48%	-9.61%	-40.65%	+89.97%
HOWL Werewolf Therapeutics	0.00%	+1.91%	+10.00%	-21.43%	-70.02%
IBIO iBio	0.00%	+1.42%	+5.93%	-2.72%	+142,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	2.50	Moderate Buy	$13.50	592.31% Upside
CYPH Cypherpunk Technologies	2.50	Moderate Buy	$0.90	39.75% Upside
HOWL Werewolf Therapeutics	2.14	Hold	$3.75	826.61% Upside
IBIO iBio	3.13	Buy	$5.00	249.65% Upside

Current Analyst Ratings Breakdown

Latest HOWL, ACRV, IBIO, and CYPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/31/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/15/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/10/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/3/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
7/2/2026	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
7/1/2026	CYPH Cypherpunk Technologies	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$0.90
6/29/2026	ACRV Acrivon Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	CYPH Cypherpunk Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	IBIO iBio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$2.02 per share	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	$1.29 per share	N/A
HOWL Werewolf Therapeutics	$1.88M	10.46	N/A	N/A	$0.34 per share	1.19
IBIO iBio	$400K	177.61	N/A	N/A	$0.90 per share	1.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$77.90M	-$1.88	N/A	N/A	N/A	N/A	-70.14%	-61.60%	N/A
CYPH Cypherpunk Technologies	$4.82M	$0.56	1.15	N/A	N/A	N/A	-20.76%	-19.48%	N/A
HOWL Werewolf Therapeutics	-$60.82M	-$0.76	N/A	N/A	N/A	N/A	-166.99%	-59.88%	11/3/2026 (Estimated)
IBIO iBio	-$18.38M	-$0.58	N/A	N/A	N/A	N/A	-53.86%	-46.48%	9/4/2026 (Estimated)

Latest HOWL, ACRV, IBIO, and CYPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/4/2026	Q4 2026	IBIO iBio	-$0.07	N/A	N/A	N/A	$0.08 million	N/A
8/12/2026	Q2 2026	ACRV Acrivon Therapeutics	-$0.5022	-$0.43	+$0.0722	-$0.43	$0.39 million	N/A
8/12/2026	Q2 2026	CYPH Cypherpunk Technologies	N/A	$0.18	N/A	$0.18	N/A	N/A
7/31/2026	Q2 2026	HOWL Werewolf Therapeutics	-$0.28	$0.08	+$0.36	$0.08	$21.00 million	$21.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
CYPH Cypherpunk Technologies	N/A	N/A	N/A	N/A	N/A
HOWL Werewolf Therapeutics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	7.99	8.98
CYPH Cypherpunk Technologies	N/A	79.19	27.28
HOWL Werewolf Therapeutics	N/A	2.91	2.91
IBIO iBio	N/A	11.88	11.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
CYPH Cypherpunk Technologies	30.46%
HOWL Werewolf Therapeutics	64.84%
IBIO iBio	7.90%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	10.50%
CYPH Cypherpunk Technologies	3.50%
HOWL Werewolf Therapeutics	23.60%
IBIO iBio	2.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	42.80 million	38.31 million	Not Optionable
CYPH Cypherpunk Technologies	40	107.76 million	103.99 million	Optionable
HOWL Werewolf Therapeutics	40	48.60 million	37.13 million	Optionable
IBIO iBio	100	49.68 million	48.31 million	N/A

HOWL, ACRV, IBIO, and CYPH Headlines

Recent News About These Companies

iBio (NASDAQ:IBIO) Upgraded by Wall Street Zen to "Hold" Rating

August 15 at 1:43 AM | americanbankingnews.com

iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen

August 15 at 1:41 AM | marketbeat.com

iBio, Inc. (NASDAQ:IBIO) Given Average Rating of "Buy" by Analysts

August 9, 2026 | marketbeat.com

Pharos iBio Selected for National AI Drug Development Project

August 6, 2026 | asiae.co.krA

iBio, Inc. annonce la nomination de Molly Carr au poste de directrice médicale

August 6, 2026 | zonebourse.comZ

iBio Names Dr. Molly Carr as Chief Medical Officer to Advance Clinical-Stage Pipeline

August 4, 2026 | quiverquant.comQ

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

August 4, 2026 | globenewswire.com

Affinity Asset Advisors LLC Grows Position in iBio, Inc. $IBIO

July 25, 2026 | marketbeat.com

iBio Updates Governance Deadlines for 2026 Annual Meeting

July 17, 2026 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Candel Therapeutics (CADL) and Ibio (IBIO)

July 3, 2026 | theglobeandmail.com

iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study

July 1, 2026 | globenewswire.com

Could iBio (IBIO) Be an Underrated Obesity Stock?

June 11, 2026 | insidermonkey.com

5 Under-the-Radar AI Stocks to Buy in 2026

June 11, 2026 | insidermonkey.com

iBio to Participate in Upcoming Healthcare Investor Conferences

June 2, 2026 | globenewswire.com

iBio, Inc.: iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

June 2, 2026 | finanznachrichten.de

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

June 2, 2026 | globenewswire.com

Three Speculative Biotech Penny Stocks With Pipeline Catalysts

May 27, 2026 | kalkinemedia.comK

iBio Strengthens Board with Appointment of Dr. Stoner

May 21, 2026 | theglobeandmail.com

We're Not Very Worried About iBio's (NASDAQ:IBIO) Cash Burn Rate

May 15, 2026 | finance.yahoo.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ibio (IBIO), MaxCyte (MXCT) and Atea Pharmaceuticals (AVIR)

May 14, 2026 | theglobeandmail.com

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

May 12, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, ACRV, IBIO, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.95 +0.10 (+5.41%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.96 +0.01 (+0.51%)

As of 08/14/2026 07:39 PM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Cypherpunk Technologies NASDAQ:CYPH

$0.64 0.00 (-0.62%)

As of 08/14/2026 04:00 PM Eastern

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Werewolf Therapeutics NASDAQ:HOWL

$0.40 +0.02 (+4.84%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.40 +0.00 (+0.07%)

As of 08/14/2026 07:34 PM Eastern

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

iBio NASDAQ:IBIO

$1.43 +0.03 (+2.14%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$1.40 -0.03 (-1.82%)

As of 08/14/2026 07:58 PM Eastern

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, ACRV, IBIO, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, ACRV, IBIO, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, ACRV, IBIO, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, ACRV, IBIO, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cypherpunk Technologies NASDAQ:CYPH

Werewolf Therapeutics NASDAQ:HOWL

iBio NASDAQ:IBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HOWL, ACRV, IBIO, and CYPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HOWL, ACRV, IBIO, and CYPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HOWL, ACRV, IBIO, and CYPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOWL, ACRV, IBIO, and CYPH Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

Cypherpunk Technologies NASDAQ:CYPH

Werewolf Therapeutics NASDAQ:HOWL

iBio NASDAQ:IBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools